(Q37771644)

22 August 2017

1 reference

title

From receptor pharmacology to improved outcomes: individualising the selection, dosing, and switching of antipsychotics (English)

1 reference

22 August 2017

1 reference

C U Correll

1

1 reference

22 August 2017

language of work or name

English

0 references

publication date

1 June 2010

1 reference

22 August 2017

1 reference

22 August 2017

volume

25 Suppl 2

1 reference

22 August 2017

page(s)

S12-21

1 reference

A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia

22 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0924-9338%2810%2971701-6

7 January 2021

A positron emission tomography study of quetiapine in schizophrenia: a preliminary finding of an antipsychotic effect with only transiently high dopamine D2 receptor occupancy

1 reference

https://api.crossref.org/works/10.1016%2FS0924-9338%2810%2971701-6

7 January 2021

Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0924-9338%2810%2971701-6

7 January 2021

Typical and atypical antipsychotics--the misleading dichotomy. Results from the Working Group 'Drugs in Psychiatry' (AGATE).

1 reference

https://api.crossref.org/works/10.1016%2FS0924-9338%2810%2971701-6

7 January 2021

Real-life dosing with second-generation antipsychotics

1 reference

https://api.crossref.org/works/10.1016%2FS0924-9338%2810%2971701-6

7 January 2021

Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0924-9338%2810%2971701-6

7 January 2021

Antipsychotic use in children and adolescents: minimizing adverse effects to maximize outcomes

1 reference

https://api.crossref.org/works/10.1016%2FS0924-9338%2810%2971701-6

7 January 2021

Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies

1 reference

https://api.crossref.org/works/10.1016%2FS0924-9338%2810%2971701-6

7 January 2021

Second-generation antipsychotic agents in the treatment of acute mania: a systematic review and meta-analysis of randomized controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS0924-9338%2810%2971701-6

7 January 2021

Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors

1 reference

https://api.crossref.org/works/10.1016%2FS0924-9338%2810%2971701-6

7 January 2021

Atypical antipsychotics in primary generalized anxiety disorder or comorbid with mood disorders.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-9338%2810%2971701-6

7 January 2021

Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-9338%2810%2971701-6

7 January 2021

Antipsychotic and mood stabilizer efficacy and tolerability in pediatric and adult patients with bipolar I mania: a comparative analysis of acute, randomized, placebo-controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS0924-9338%2810%2971701-6

7 January 2021

Balancing efficacy and safety in treatment with antipsychotics.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-9338%2810%2971701-6

7 January 2021

Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials

1 reference

https://api.crossref.org/works/10.1016%2FS0924-9338%2810%2971701-6

7 January 2021

Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0924-9338%2810%2971701-6

7 January 2021

The crossover approach to switching antipsychotics: what is the evidence?

1 reference

https://api.crossref.org/works/10.1016%2FS0924-9338%2810%2971701-6

7 January 2021

A UK audit of screening for the metabolic side effects of antipsychotics in community patients

1 reference

https://api.crossref.org/works/10.1016%2FS0924-9338%2810%2971701-6

7 January 2021

How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS0924-9338%2810%2971701-6

7 January 2021

Risperidone and haloperidol in first-episode psychosis: a long-term randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0924-9338%2810%2971701-6

7 January 2021

Treatment of bipolar disorder: a systematic review of available data and clinical perspectives

1 reference

https://api.crossref.org/works/10.1016%2FS0924-9338%2810%2971701-6

7 January 2021

Metabolic testing rates in 3 state Medicaid programs after FDA warnings and ADA/APA recommendations for second-generation antipsychotic drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0924-9338%2810%2971701-6

7 January 2021

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0924-9338%2810%2971701-6

7 January 2021

Real-life switching strategies with second-generation antipsychotics.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-9338%2810%2971701-6

7 January 2021

10.1016/S0924-9338(10)71701-6

Identifiers

DOI

1 reference

22 August 2017

1 reference